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Spinal cord injury (SCI), damage of the spinalcord that results in complete or incomplete lossof sensation and/or mobility, is one of the most
devastating traumatic conditions that can be encoun-
tered by many patients. The pathophysiology of SCI
includes the primary damages caused immediately by
mechanical forces imparted to the spinal cord and the
following secondary damages including processes such
as ischemia, inflammation, ionic homeostasis and
apoptotic cell death.1-2 These secondary injury processes
also includeglutamate-mediatedcalcineurinactivation,bcl-
2 antagonist cell death (BAD, a proapoptotic member of
the bcl-2 gene family) dephosphorylation,3 prolonged
purinergic receptor activation,4 exposure of K+ chan-
nels across the demyelinated axonal region5 and accu-
mulation of intracellular sodium as a result of trauma-
induced perturbation of voltage-sensitive sodium chan-
nel activity 6. Recent studies indicated that, in addition
to the physiological functions, the activation of micro-
glia cells and astrocytes and the degeneration of oligo-
dendrocytes are important outcomes of the pathophysi-
ology of acute SCI7 and glial transplantation is a prom-
ising therapy for SCI8-11.
Glial mechanism of SCI
Neuroglial cells, represented mainly by oligoden-
drocytes, astrocytes and microglia cells, show numerous
vital functions in the central nervous system (CNS), such
as shaping the micro-architecture of the brain matters,
being involved in information transfer and central
sensitization, receiving synaptic inputs, releasing
gliotransmitters, producing long-range information ex-
change and acting as pluripotent neural precursors/
stem cells.12-15 Recent studies indicate that clinically-
relevant incomplete contusive SCI results in significant
loss of axons and glia in the peripheral rim of residual
white matter spared by injury16-17 and that the axonal
loss is permanent but the lost glia is largely replaced in
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the residual white matter 6-8 weeks after SCI 17-18, sug-
gesting the involvement of glial cells after SCI.
Decades of studies have pointed out that apoptosis
or programmed cell death of oligodendrocytes is one
important pathophysiological mechanism of SCI.19 The
pathophysiological apoptosis of oligodendrocytes may
be due to the alpha-amino-3-hydroxy-5-methyl-4-
osoxazolepropionic acid/kainic acid (AMPA/KA) recep-
tor-mediated toxicity by high concentrations of
glutamate following SCI20 since quantification of AMPA-
expressing cells in the white matter of the spinal cord
indicates predominant GluR3 expression in oligoden-
drocytes and a large decline in GluR3-expressing oli-
godendrocytes after SCI21. Recent studies also indi-
cate that N-methyl-D-aspartate (NMDA) receptors are
expressed in oligodendrocytes and play some impor-
tant roles in ischemic diseases.22 These studies simul-
taneously indicate that the activities of glutamate re-
ceptorsof oligodendrocytesare involvedin SCI and may
be potential therapeutic target for SCI. SCI-induced
apoptotic cell death or degenerationof oligodendrocytes
will induce myelin degeneration and cause additional
disturbances of axonal function.23 Oligodendrocyte
apoptosis and axon demyelination occurring after SCI
showed that dynamic changes occurred during the late
stage after injury and oligodendrocytesmay be replaced.
However, through proliferatingneuro-gliaantigen 2 (NG2)
(+) progenitor cells, neural tumor-derived cell line had
mixed properties of neurons and glial cells.24 In addition,
apoptosis of oligodendrocytes after SCI may be also
associated with apoptosis-1 (apo-1), CD95 (FAS) and
p75,19 c-Jun N-terminal kinase 3 (JNK3) and proteins
interacting with the mitotic kinase, nerves in mitosis A I
(Pin1)25 and some oligodendrocyte/myelin-derived ax-
onal inhibitory molecules, such as Nogo-A, myelin-as-
sociated glycoprotein (MAG) and oligodendrocyte my-
elin glycoprotein (OmgP).26-27
Increasing evidences have indicated that the activa-
tion of astrocytes and microglia cells also contributes
to the pathophysiology of SCI. Severely-activated as-
trocytes may worsen the inflammatory conditions and
affect the survival of neurons through secreting exces-
sive proinflammatory cytotoxic cytokines, chemokines
and neurotoxic substances, such as the tumor necro-
sis factor-alpha (TNF-) that kills oligodendrocytes and
the neurotrophin receptor p75 expressed in both neu-
rons and oligodendrocytes after SCI. Astrocytes also
undergo changes in the expression of channels and
transporters, which could contribute to abnormal excit-
ability andexcitotoxicity of neurons.7, 28, 29 After SCI, water
channel aquaporin 4, expressed only by astrocytes,
displays early down-regulation at the injury site followed
by persistent up-regulation that correlates with increased
water content.30 Another detrimental effect of the for-
mation of glial scar is the up-regulation of chondroitin
sulfate proteoglycans (CSPGs), the key components
of the extracellular matrix in the nervous system. These
molecules, after injury, are secreted by reactive astro-
cytes and are potent inhibitors for axonal regrowth.31
However, some studies indicate that, after SCI, reac-
tive astrocytes isolate intact tissues from the lesion,
control theconcentrationof ions, neurotransmitters, neu-
rotrophic factors and metabolic products in the extracel-
lular space, attenuate inflammation, promote the repair of
blood-brain barrier and the survival of neurons and
oligodendrocytes,31, 32 suggesting that reactive astrocytes
provide essential activities that protect the tissues and
preserve the functions after mild or moderate SCI.
Similarly, in culture of spinal cord neurons, it shows
that astrocytes can mediate the neuroprotective effect
of uric acid against glutamate neurotoxicity.33
Additionally, proliferation of glial cells also occurs
after SCI. After a standardized contusive SCI, cell pro-
liferation including oligodendrocytes, astrocytes, micro-
glia/macrophages, and a high proportion of NG2(+) glial
precursors, reaches peak 3 days after injury and con-
tinues to be significantly higher than the normal level for
many weeks.34 Some of these dividing cells can differen-
tiate in vivo into mature oligodendrocytes or astrocytes,34
while the number of oligodendrocytes at the impact site is
reduced by 93% 7 days after injury but increases three
folds 14 days after injury.35 These results imply one po-
tential role of glial cells in treating SCI.
Implications of glial cells in transplantation
therapy of SCI
Most SCIs lead to more or less severe and perma-
nent neurological deficits. Although transplantation of
embryonic stem cells or neural progenitor cells is an
attractive strategy for repair of the injured spinal cord,
transplantation of these cells alone for acute SCI has
not resulted in robust axon regeneration beyond the
sites of injury. This may be due to the progenitor cells
differentiating to the cell types that support axon growth
poorly and/or their inability to modify the inhibitory envi-
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ronment of adult CNS after injuries. Recent animal stud-
ies have shown that glial cells and/or glial progenitor
cells, including NG2, Schwann cells (SCs), radial glial
cells (RGCs), oligodendrocytes, astrocytes and micro-
glia cells, are present in the normal adult spinal cord
and appear to be stimulated to proliferate after SCI,35-37
holding promise to enhance the functional recovery of
injured spinal cord38-40.
SCs and RGCs SCs are among the most promis-
ing candidates for autologous grafting. They can
remyelinate the spinal cord lesions after experimental
demyelination, leading to functional recovery in some
cases of rodent and primate models.41 However, be-
cause the capacity of axonal regeneration is limited in
the spinal cord, SCs cannot normally enter the CNS,
and the migration of transplanted SCs in the white mat-
ter of CNS is inhibited by astrocytes, the functional
recovery is minimal. Co-transplantationof SCs with pre-
differentiated neural stem cells (NSCs) in vitro could
mildly improve the neural differentiation of NSCs in vivo
and the injured animals were improved both function-
ally and structurally, including improved Basso, Beattie,
and Bresnahan (BBB) scores, increased axonal regen-
eration/remyelination, and reduced neuronal loss.42 SCs
may also contribute to neuronal differentiation of NSCs
in vitro and in vivo, thereby, may be helpful for the
therapy of SCI. It is found that SCs dissociated and
purified simultaneously from the sciatic nerves of 4-day-
old rats can significantly increase both the number of
survived NSCs dissociated and cloned from the hip-
pocampal tissues of newborn rats and the number of
differentiated neuron-like cells that develope axon-like
processes, demonstrating that SCs can promote the
survival and differentiation of transplanted NSCs in the
injured spinal cord.43 Furthermore, incoculture withSCs,
NSCs can differentiate into neurons more readily in the
rats with spinal cord contusion injury who have under-
gone transplantation of NSCs and SCs into the intraspi-
nal cavity, which demonstrates a moderate improve-
ment in motor functions.44 Therefore, transplantation of
NSCs and SCs into the affected area may be a feasible
approach for promoting motor recovery in patients with
SCI. However, in the study with olfactory ensheathing
cells (OECs) and SCs implanted into the intact spinal
cord after dorsal column crush (DCC) injury, both OECs
and SCs are able to support the axonal re-growth and/or
sprout into the lesions.45
In the development of the CNS, RGCs are among
the first cells derived from neuroepithelial cells. Recent
studies have reported that radial glia possesses the
properties of NSCs and there is temporal progressive
antigen expression in radial glia after contusive SCI in
adult rats.46,47 The acutely-transplanted RGCs can mi-
grate to form bridges across the spinal cord lesions in
vivo and promote the functional recovery of the injured
spinal cord through protecting it against macrophages
and secondary damages.48
Oligodendrocytes Oligodendrocyte apoptosis is
one important pathological mechanism after SCI, while
human embryonic stem cell (hESC)-derived oligoden-
drocyte progenitor cells (OPCs) can express the func-
tional levels of multiple factors with trophic effects on
neurons.8 The neurotrophic activity of hESC-derived
OPCs is further demonstrated by their stimulated ef-
fects on the neurite outgrowth of sensory neurons of
adult rats in vitro,8 which suggests that neurotrophic
factors derived from OPCs can impact the survival of
axotomized neurons, promote axonal regeneration in
interrupted conduction pathways as well as contribute
to the functional recovery. In another study, hESC-de-
rived OPCs injected 7 days or 10 months after injury
survived, redistributed over short distances, and differ-
entiated into oligodendrocytes. Animals that received
OPCs 7 days af ter injury exhibited enhanced
remyelination and substantially-improved locomotor
ability. In contrast, when OPCs were transplanted 10
months after injury, therewasnoenhanced remyelination
or locomotor recovery.49 Furthermore, transplantation of
hESC-derived OPCs into the contusive SCI sites in adult
rats (200 u) can enhance remyelination and promote
the recovery of motor function and acorrelation between
the presence of demyelinating pathology and the sur-
vival and migration rates of the transplanted cells has
been noted. However, the transplanted cells in the 50 u
injury group survived, exhibited limited migration, but
failed to induce remyelination as demyelination in this
injury group was absent. The animals receiving a 50 u
injury displayed only a transient decline in locomotor
function. Importantly, hESC-derived OPCstransplanted
into the 50 u injury group did not cause a further de-
cline in locomotion,50 suggesting that a demyelinating
pathology is important as a prerequisite for the function
of transplanted myelinogenic cells and that transplan-
tation of hESC-derived OPCs into the injuredspinal cord
is a promising approach without any harm. These stud-
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ies document the feasibility of predifferentiating hESCs
into functional OPCs and demonstrate their therapeu-
tic potential via the effect of neurotrophic factors at early
time points after SCI.
Astrocytes It has been well documented that, in
adult rats, astrocytes in the subventricular zone and
subgranular layer of the dentate gyrus are NSCs. In
either hemi-transectioned or longitudinally-cut spinal
cord, there is widespread nestin expression in astro-
cytes of both the gray and white matters. Culture of the
nestin-immunoreactiveastrocytes of the lateral cord can
generate neurospheres, the cells of which have the abil-
ity of self-renewal and are able to differentiate into
neurons, astrocytes, or oligodendrocytes.10 Transplan-
tation of astrocytes derived from embryonic glial-re-
stricted precursors (GRPs) can promote robust growth
of over 60% axons to ascend dorsal column into the
centers of the lesions with 66% of these axons extend-
ing beyond the injury sites and restore the locomotor
function after acute transection injuries of spinal cord
of adult rats. Grid-walk analysis of GRPs-derived astro-
cytes (GDAs)-transplanted rats with rubrospinal tract
injuries reveals significant improvements in locomotor
function. GDA transplantation also induces a striking
realignment of injured tissues, suppresses initial scar-
ring and rescues axotomized CNS neurons with cut
axons from atrophy. In sharp contrast, undifferentiated
GRPs fail to suppress scar formation or support axon
growth and locomotor recovery.51 These results sug-
gest that pre-differentiation of glial precursors into GDAs
before transplantation into the injured spinal cord leads
to significantly-improved outcomes over precursor cell
transplantation, providing both a novel strategy and a
highly-effective new cell type for repairing CNS injuries.
The contribution of astrocytes to SCI may be related
with the remyelination because oligodendrocyte-type 2
astrocyte (O-2A) progenitor cells have been reported to
remyelinate the focal areas of demyelinated spinal cord
in adult rats and O-2A cells transplanted into the sites
of SCI induced with a New York University (NYU) im-
pactor at T9 of ratscouldsignificantly improve thebehavior
function.52
Microglia Additionally, the well-regulated activi-
ties of microglia and T cells specific to CNS antigens
can contribute to the protection of CNS neural cells
and their renewal from adult neural stem/progenitor cells
(aNPCs). T cell-based vaccination of mice with a my-
elin-derived peptide, when combined with transplanta-
tion of aNPCs into the cerebrospinal fluid (CSF), can
synergistically promote the functional recovery of in-
jured spinal cord. The synergistic effect is correlated
with the modulation of the nature and intensity of local
T cells, microglial response, expressionof brain-derived
neurotrophic factors and noggin proteins, and appear-
ance of newly-formed neurons from endogenous pre-
cursor-cell pools. These results substantiate the con-
tention that the local immune response plays a crucial
role in recruitment of aNPCs to the lesion site and sug-
gest that similar immunological manipulations might
also serve as a therapeutic means for controlled migra-
tionof stem/progenitor cells toother acutely-injuredCNS
sites.53
Olfactory ensheathing SCs (OESCs) OESCs are
unique glial cells, which have the ability to encourage
nerve fibres to grow and may be used for treating spinal
cord and brachial plexus injuries,54 while in the study
using OESCs and SCs implantation after dorsal col-
umn crush (DCC) injury, both OESCs and SCs are able
to support axonal re-growth and/or sprout into the
lesions. These studies demonstrate the potential thera-
peutic roleof OESCs after SCI. Transplantation of grafts
of nasal olfactory mucosa containing OESCs into the
partially-removed rat spinal cord can partially recover
the movement of hindlimbs and joints. Corticospinal
tracing indicates that olfactory mucosa transplantation
can restore the severed tract.55 Clinical studies on trans-
planting OESCsinto patients withSCI have beenmade in
China, Portugal, andother countriesandareas.56 Although
there are some positive effects of the transplanted
OESCs on axonal regeneration after SCI, the effects
and the underlying mechanism of these grafted OESCs
on NPCs are not well understood and a number of con-
troversial issues related to OESC biology and trans-
plantation must be addressed to understand the ratio-
nale and expectations for OEC cell therapy approaches
after SCI.56 A recent study indicates that the effect of
OESCs may be related with the OESCs-derived soluble
factors that regulate the proliferation and differentiation
of rat NPCs. The conditioned medium from cultured
OESCs shows that it can promote the proliferation and
inhibit the neuronal differentiation of NPCs.57 But accu-
mulating anatomical evidences indicate that although
axons regenerate within a transplant with OESCs, they
do not cross the lesions or reconnect with the neurons
on the opposite side to any significant extent and there
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are several contradictory reports on the migratory and
axon growth-supporting properties of transplanted
OESCs.58,59 It suggests that neuroprotection and pro-
motion of the sprout from the intact fibers may be the
main mechanisms contributing to the functional
recovery. These findings also reveal the likely limitation
of OESCs transplantation for SCI repair and therefore,
OESCs transplantation for SCI still has a long way to
go.60
Some factors should be considered when perform-
ing transplantations for SCI, such as time window and
transplant site. It showed that a significant increase in
cell survival 7 days after SCI was found in the rats re-
ceiving rostral and caudal injections of NSCs as com-
pared with the injection directly into the site of injury. A
significant increase in cell survival was also found in
the rats receiving subacute transplants 9 days after in-
jury as compared with that 28 days after injury.61 An-
other problem is the pathways for transplantation. In
the majority of reports, cell transplantation is performed
by direct local injection with a needle, which might be
too invasive for clinical use. Therefore, intravenously
delivering neural progenitor cells for the treatment of
SCI hasbeen introducedby Fujiwaraet al.62 In their study,
neural progenitor cells obtained from E15 fetal hippocam-
pus of transgenic rats expressing green fluorescent pro-
tein were transplanted intravenously 24 hoursafter contu-
sion injury and were found to migrate to the lesion site
widely and to demonstrate nestin at an early phase after
transplantation. These neural progenitor cells differenti-
ated into neurons, astrocytes and oligodendrocytes, and
survived at least for 56 days. These results indicate that
intravenously-injected NSCs can migrate into the spi-
nal cord lesion and preserve their potential as neural
progenitor cells and that this procedure is a potential
method of delivering cells into the lesion for the treat-
ment of SCI.
Perspectives of glial study in treating SCI
Past decades have witnessed increasing interests
in strategies to improve neurologic function after SCI.
But due to lack of completely understandingof thepatho-
physiologic events that occur after acute SCI, espe-
cially secondary injuries, no very effective therapy is
available for severe SCI yet. Since glial cells play vital
roles in both physiological neuron functions and patho-
physiologic disorders, including their recently-explored
functions in controlling brain microcirculation63 and se-
cretion of neurotrophic factors13, we should put more
efforts on the studies of the glial mechanism after SCI
and exploring the therapeutical strategies of transplan-
tations using glial progenitor cells. A recent study us-
ing medium with bone morphogenetic protein 4 (BMP4)
and leukemia inhibitory factor to culture fetal spinal cord
cells provided a means of obtaining pure populations of
human spinal cord-derived astrocytes, which could be
utilized for further studies of cell replacement strate-
gies or evaluationof therapeutics in vitro.64 Another study
indicated that neutralization of ciliary neurotrophic fac-
tor reduced astrocyte-mediated scar formation from
transplanted NSCs and promoted the regeneration of
corticospinal tract fibers after SCI.65 Treatment with glial
growth factor 2 and fibroblast growth factor 2 could en-
hance oligodendrogenesis and increase the number of
EGFP(neg) NG2(+) cells.66 These studies show an ex-
citing prospect for treatment of SCI with glial cells.
Due to the complicated mechanism of SCI and the
limitary effect of single transplantation, efforts have been
made to find effective combination strategies to improve
theoutcomesafter injury. Combination interventionshave
been performed including implantation of SCs plus
neuroprotective agents and growth factors administered
in various ways, OECs implantation, chondroitinase
addition,andelevationofcyclicadenosinemonophosphoric
acid (AMP). The most efficacious strategy in the acute
complete transection/SC bridge model is the combina-
tion of SCs, OECs, and chondroitinase administration
while the most successful combination strategy for a
subacute spinal cord contusion injury is transplantation
of SCs combining with elevation of cyclic AMP.67 In
addition, bone marrow stromal cells are also shown to be
helpful in OEC transplantation.68 These studies may pro-
vide one effective strategy of glial transplantation for
treating SCI.
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